drugset / Trial / NCT02065401

Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)

NCT02065401 ↗

Phase 1 Withdrawn Shire
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to compare the pharmacokinetic profiles of deferitazole after administration of granule and tablet formulations of a deferitazole disodium salt to a capsule formulation of deferitazole magnesium hydroxide salt (reference formulation) in healthy adult subjects.

Timeline

Start
2014-02-28
Primary completion
2014-03-19
Completion
2014-03-19

Outcome

Outcome not reported

Stopped: “This study was withdrawn until the evaluation of the nonclinical rat findings is complete.”

Drugs

EvaluationDrugModalityDoseRoute
Subject SPD602 Unknown 1500 mg Oral
Subject SPD602 Unknown 2400 mg Oral

Indications

No indication recorded.